Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 51Leukemia 26Myelodysplastic Syndromes 10Leukemia, Myelomonocytic, Acute 10Leukemia, Monocytic, Acute 9Leukemia, Megakaryoblastic, Acute 8Leukemia, Erythroblastic, Acute 8Congenital Abnormalities 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Blast Crisis 5Anemia, Refractory, with Excess of Blasts 5Recurrence 4Leukemia, Promyelocytic, Acute 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Eosinophilic, Acute 4Liver Neoplasms 3Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Biphenotypic, Acute 3Leukemia, Basophilic, Acute 3Carcinoma, Hepatocellular 3Myeloproliferative Disorders 2Lung Neoplasms 2Graft vs Host Disease 2Thrombocythemia, Essential 1Sarcoma, Myeloid 1Primary Myelofibrosis 1Polycythemia Vera 1Neutropenia 1

Interventions

Gemcitabine 53Bevacizumab 52Cyclophosphamide 49Docetaxel 42Carboplatin 40pembrolizumab 37Paclitaxel 36Fluorouracil 36Cisplatin 35Radiotherapy 31Oxaliplatin 31Capecitabine 29Irinotecan 28Dexamethasone 27Leucovorin 25Cetuximab 25Nivolumab 24Doxorubicin 22Drug Therapy 21Erlotinib Hydrochloride 20Pemetrexed 19durvalumab 18trametinib 17fludarabine 16atezolizumab 16Trastuzumab 16Sunitinib 16Rituximab 16Prednisone 16Sorafenib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms × Idarubicin × Clear all
NCT01035502 2013-09-27

A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia

Clavis Pharma

Phase 2 Completed
51 enrolled
Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡